New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Glucagon-Like Peptide-2 (GLP-2 ... particles that transport fats in the bloodstream—through a signaling pathway involving neuronal nitric oxide synthase (nNOS)[2]. This pathway is essential ...

"We've long known that the brain can directly signal the pancreas to release hormones quickly, but our work shows it can also indirectly boost glucagon ... neuro-immune pathways could offer ...

Liraglutide, a GLP-1 receptor agonist, has been shown to effectively lower glucagon levels and promote ... and insulin signaling pathways. Despite being in early research stages, bile acid ...

Announcing a new article publication for BIO Integration journal.   Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

ways these pathways affect every aspect of our health. As a result, semaglutide and its fellow glucagon-like peptide-1 drugs are spawning a tremendous outpouring of research that often clarifies ...

Insulin lowers blood glucose by promoting its uptake into cells, while glucagon raises it by signaling the liver ... "Targeting these neuro-immune pathways could offer a new approach to prevention ...

Hunger is an ancestral and evolutionary survival instinct; its importance is evident in the complex and redundant pathways involving ... GI gastrointestinal, GLP-1 glucagon-like peptide 1, and ...

Intermittent fasting is becoming increasingly popular. But is it helpful for weight loss and other medical conditions?